Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
Robert Wang, MD
Advertisement
Articles by Robert Wang, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Relacorilant Plus Nab-Paclitaxel Meets OS End Point of ROSELLA Trial in PROC
2
NCCN Guidelines Recognize MammaPrint/BluePrint for Determining Anthracycline Benefit in Breast Cancer
3
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
4
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
5